Camena Bioscience has appointed Gregory McGuinness as CEO as it looks to scale its antibody discovery platform. 

The biotechnology company, which sees itself as a pioneer in enzymatic DNA synthesis for AI-driven antibody discovery, has appointed McGuinness to support the company’s growth, including its commercialisation of AI-driven antibody discovery platform gSynth. 

 McGuinness was most recently CEO at Inanovate and was also CEO/Co-Founder at TwiXimo Therapeutics. He has experience in executive leadership and operational expertise, having commercialised disruptive and foundational technologies across the life sciences and diagnostics markets.  

McGuinness’ experience in scaling operations and driving product innovation will allow Camena to scale its gSynth technology platform, which the company says enables researchers to write DNA, including long, complex, and difficult-to-synthesise gene sequences, at scale and with unprecedented accuracy and speed. 

“Greg’s track record in scaling high-potential technology companies makes him the ideal choice to drive Camena through its commercialisation phase,” said Dr Aditya Rajagopal, Chair of the Board at Camena Bioscience. 

“He brings the rare ability to guide complex technical developments while building world-class operational infrastructure. With his appointment, Camena is perfectly positioned to set the global standard for DNA synthesis that is now the foundational engine for AI-based bio-innovation. I am excited to see what lies ahead for Camena.” 

“I am honoured and delighted to step into the role of CEO at Camena during such an exciting time of growth,” McGuinness added. 

“I look forward to working alongside our exceptionally talented team to build on the company’s strong foundation, delivering the highest quality products to our clients, and driving our vision for the future of AI-driven antibody discovery.”